Hypothesis

Aged cells actively suppress autophagy not only via mTORC1 hyperactivation and Rubicon accumulation, but also through a loss of gut‑derived indole‑3‑propionic acid (IPA) signaling. Declining IPA reduces Pregnane X Receptor (PXR) activity, which normally binds the Rubicon promoter and recruits corepressors to keep Rubicon transcription low. When IPA‑PXR signaling wanes, Rubicon expression rises, blocking autophagosome‑lysosome fusion and compounding the autophagy block imposed by mTORC1. Restoring IPA should therefore lower Rubicon levels and revive flux, an effect that disappears in PXR‑deficient cells.

Mechanistic Model

1. IPA → PXR activation – Microbial IPA ligands PXR, promoting its nuclear translocation and DNA binding.
2. PXR represses Rubicon – PXR interacts with HDAC3/SMRT corepressor complexes at the Rubicon enhancer, decreasing histone acetylation and transcription.
3. Low IPA → ↓PXR activity – Age‑related microbiome shifts cut IPA production, diminishing PXR‑mediated repression.
4. Rubicon up‑regulation – Elevated Rubicon impairs SNARE‑mediated lysosome fusion, stalling autophagosome maturation.
5. Feedback – Persistent autophagic stress further inhibits mTORC1‑independent pathways, reinforcing the suppression loop.

This model adds a transcriptional layer to the known post‑translational (acetylation of ATG proteins) and signaling (mTORC1, PPT1) controls described in et al.

Testable Predictions

• Prediction 1: In wild‑type aged mice, oral IPA supplementation will reduce Rubicon mRNA and protein levels in liver and muscle, concomitant with increased LC3‑II/I ratio and decreased p62.
• Prediction 2: The same IPA treatment will fail to lower Rubicon or improve flux in PXR‑knockout littermates, despite normal mTORC1 inhibition.
• Prediction 3: Chromatin immunoprecipitation (ChIP) will show PXR occupancy at the Rubicon promoter in young tissue that declines with age and is rescued by IPA.
• Prediction 4: Overexpressing a constitutively active PXR in aged fibroblasts will suppress Rubicon expression even without IPA, restoring autophagosome‑lysosome fusion measured by mRFP‑GFP‑LC3 assay.

Experimental Design

1. Animal study – 20‑month‑old C57BL/6J and PXR^−/− mice receive IPA (10 mg/kg/day) or vehicle for 4 weeks. Tissues harvested for Western blot (Rubicon, LC3, p62), qPCR, and immunofluorescence.
2. In vitro validation – Primary hepatocytes from young and old mice treated with IPA (± PXR inhibitor GSK‑808). Measure Rubicon promoter activity via luciferase reporter and autophagic flux using bafilomycin A1 chase.
3. Rescue assay – Transduce aged PXR^−/− fibroblasts with adenoviral PXR; assess whether Rubicon downregulation and flux recovery occur without IPA.

Potential Pitfalls & Alternatives

• If IPA reduces Rubicon independently of PXR, the hypothesis would need revision to include alternative receptors (e.g., AhR).
• Compensatory upregulation of other autophagy inhibitors (e.g., Bcl‑2) could mask effects; combinatorial knockdowns may be required.
• Microbiota variability could confound IPA levels; using germ‑colonized flora with defined tryptophan‑metabolizing strains would improve reproducibility.

By linking microbial metabolite signaling to transcriptional control of a core autophagy brake, this hypothesis extends the framework and offers a clear, falsifiable route to therapeutically re‑engage cellular cleanup in aging.